![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
http://www.pharmafile.com/news/536089/galderma-acne-treatment-receives-approval-europe
https://www.prnewswire.com/news-releases/galderma-demonstrates-robust-aesthetic-innovation-pipeline-with-initiation-of-seven-new-clinical-studies-300944430.html
https://www.prnewswire.com/news-releases/galderma-announces-positive-phase-2-results-for-its-proprietary-liquid-formulation-of-an-investigational-botulinum-toxin-and-approval-of-new-state-of-the-art-manufacturing-facility-300934292.html
https://www.prnewswire.com/news-releases/galderma-receives-fda-approval-for-aklief-trifarotene-cream-0-005-the-first-new-retinoid-molecule-for-the-treatment-of-acne-in-over-20-years-300931400.html
https://www.businesswire.com/news/home/20190308005203/en/Galderma-Presented-Final-Results-Phase-2b-Study/?feedref=JjAwJuNHiystnCoBq_hl-QyNsUQ29c24MKpwrFSKUOTZQK86VRF04E6aMvZHPoaH7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LP6oD-t3eB0qV-nJQ-WeFyCEq7XOd8em_Uy42DWNTo2Mw==
https://www.pharmacompass.com/pdf/news/soolantra-ivermectin-galderma-lab-v-actavis-lab-teva-usa-1513579526.pdf
https://www.pharmacompass.com/pdf/news/soolantra-ivermectin-galderma-laboratories-v-perrigo-uk-finco-1500533211.pdf
https://www.pharmacompass.com/pdf/news/soolantra-ivermectin-galderma-laboratoriesnestle-skin-health-actavis-teva-inc-1494842969.pdf